Go Pro
OTCMKTS:MKGAF

Merck KGaA (MKGAF) Stock Price, News & Analysis

Merck KGaA logo
$158.15 -6.43 (-3.91%)
As of 03:15 PM Eastern

About Merck KGaA Stock (OTCMKTS:MKGAF)

Advanced

Key Stats

Today's Range
$157.38
$167.25
50-Day Range
$149.28
$174.77
52-Week Range
$116.68
$175.56
Volume
338 shs
Average Volume
612 shs
Market Capitalization
$20.44 billion
P/E Ratio
24.14
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company’s operations are organized mainly into three businesses. Its Healthcare division develops and commercializes prescription pharmaceuticals and biopharmaceutical therapies across areas such as oncology, immunology and fertility, and it provides related clinical development and manufacturing capabilities. The Life Science business supplies research- and manufacturing-critical products and services to academic, biotech and pharmaceutical customers worldwide — including lab reagents, filters, chromatography media and instruments; in the U.S. and Canada this business is widely known under the MilliporeSigma name following strategic acquisitions. The Performance Materials segment produces specialty chemicals and advanced materials for electronics, display and semiconductor applications, offering materials used in consumer electronics, data centers and industrial processes.

Merck KGaA has grown through a combination of internal R&D and strategic acquisitions, notably expanding its life science footprint through the acquisitions of Millipore and Sigma-Aldrich. The company emphasizes investment in research and development, partnerships with academic and industry collaborators, and global manufacturing and distribution networks to support clients across the pharmaceutical, biotechnology and high-tech supply chains. In North America, certain pharmaceutical activities operate under the EMD Serono brand to reflect regional branding conventions.

Leadership is focused on strengthening innovation and sustainable growth; Belén Garijo serves as Chair of the Executive Board and CEO, bringing experience from the company’s healthcare operations. Merck KGaA’s diversified mix of pharmaceuticals, life-science tools and performance materials positions it as a broad-based supplier to both healthcare and high-tech industries with a global footprint and long history of scientific activity.

AI Generated. May Contain Errors.

Merck KGaA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

MKGAF MarketRank™: 

Merck KGaA scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Merck KGaA.

  • Earnings Growth

    Earnings for Merck KGaA are expected to grow by 8.21% in the coming year, from $9.75 to $10.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merck KGaA is 24.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.22.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merck KGaA is 24.14, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.31.

  • Price to Book Value per Share Ratio

    Merck KGaA has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Merck KGaA's valuation and earnings.
  • Percentage of Shares Shorted

    0.54% of the float of Merck KGaA has been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 722.97, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Merck KGaA has recently increased by 12.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Merck KGaA does not currently pay a dividend.

  • Dividend Growth

    Merck KGaA does not have a long track record of dividend growth.

  • News Sentiment

    Merck KGaA has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Merck KGaA this week, compared to 1 article on an average week.
Receive MKGAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MKGAF Stock News Headlines

Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
See More Headlines

MKGAF Stock Analysis - Frequently Asked Questions

Merck KGaA's stock was trading at $147.60 at the start of the year. Since then, MKGAF shares have increased by 7.1% and is now trading at $158.1480.

Top institutional investors of Merck KGaA include Bank of America Corp DE (23.63%), Legal & General Group Plc (14.60%), Barrow Hanley Mewhinney & Strauss LLC (5.67%) and Caisse de depot et placement du Quebec (3.44%).

Shares of MKGAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/27/2026
Next Earnings (Estimated)
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:MKGAF
CIK
N/A
Employees
62,908
Year Founded
1891

Profitability

EPS (Trailing Twelve Months)
$6.81
Trailing P/E Ratio
24.14
Forward P/E Ratio
16.22
P/E Growth
N/A
Net Income
$3.06 billion
Net Margins
12.60%
Pretax Margin
15.64%
Return on Equity
10.17%
Return on Assets
5.74%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
1.31
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$22.72 billion
Price / Sales
0.90
Cash Flow
$47.63 per share
Price / Cash Flow
3.32
Book Value
$212.00 per share
Price / Book
0.75

Miscellaneous

Outstanding Shares
129,240,000
Free Float
N/A
Market Cap
$20.44 billion
Optionable
Not Optionable
Beta
0.96

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:MKGAF) was last updated on 8/27/2026 by MarketBeat.com Staff.
From Our Partners